COVID-19Data ExclusivitiesTrade Policy Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?August 17, 2021 This post introduces my chapter the Special 301 Report in the newly-published book Intellectual Property…Michael Palmedo Data ExclusivitiesTRIPS Data Exclusivity and Trips Flexibilities: Going Back to the BasicsAugust 18, 2020 The COVID-19 pandemic has provided enough food for thought to reconsider public healthcare issues and…Sonal Singh Data ExclusivitiesPatents Is it Time to Do Away with Data Exclusivity?July 8, 2020 If there is a lesson from COVID-19, it is the need to look at the…Srividhya RagavanJonathan Kimball Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Search Search Blog Front Page CategoriesCategories Select Category COVID-19 (21) Data Exclusivities (5) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (16) Right to Health (2) TAMU (1) Trade Policy (2) TRIPS (20) TRIPS Flexibilities (3) Vaccines (5) Voluntary Licenses (1) Archives Archives Select Month October 2021 September 2021 August 2021 July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (13) Srividhya Ragavan (10) Shirin Syed (2) Michael Palmedo (3) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS Excerpts from the Webinar: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Expand the Study of Intellectual Property Rights The Overlooked Role of Copyright in Securing Vaccine Distribution Equity WEBINAR: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?
Data ExclusivitiesTRIPS Data Exclusivity and Trips Flexibilities: Going Back to the BasicsAugust 18, 2020 The COVID-19 pandemic has provided enough food for thought to reconsider public healthcare issues and…Sonal Singh Data ExclusivitiesPatents Is it Time to Do Away with Data Exclusivity?July 8, 2020 If there is a lesson from COVID-19, it is the need to look at the…Srividhya RagavanJonathan Kimball Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Search Search Blog Front Page CategoriesCategories Select Category COVID-19 (21) Data Exclusivities (5) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (16) Right to Health (2) TAMU (1) Trade Policy (2) TRIPS (20) TRIPS Flexibilities (3) Vaccines (5) Voluntary Licenses (1) Archives Archives Select Month October 2021 September 2021 August 2021 July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (13) Srividhya Ragavan (10) Shirin Syed (2) Michael Palmedo (3) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS Excerpts from the Webinar: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Expand the Study of Intellectual Property Rights The Overlooked Role of Copyright in Securing Vaccine Distribution Equity WEBINAR: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?
Data ExclusivitiesPatents Is it Time to Do Away with Data Exclusivity?July 8, 2020 If there is a lesson from COVID-19, it is the need to look at the…Srividhya RagavanJonathan Kimball Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Search Search Blog Front Page CategoriesCategories Select Category COVID-19 (21) Data Exclusivities (5) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (16) Right to Health (2) TAMU (1) Trade Policy (2) TRIPS (20) TRIPS Flexibilities (3) Vaccines (5) Voluntary Licenses (1) Archives Archives Select Month October 2021 September 2021 August 2021 July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (13) Srividhya Ragavan (10) Shirin Syed (2) Michael Palmedo (3) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS Excerpts from the Webinar: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Expand the Study of Intellectual Property Rights The Overlooked Role of Copyright in Securing Vaccine Distribution Equity WEBINAR: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Search Search Blog Front Page CategoriesCategories Select Category COVID-19 (21) Data Exclusivities (5) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (16) Right to Health (2) TAMU (1) Trade Policy (2) TRIPS (20) TRIPS Flexibilities (3) Vaccines (5) Voluntary Licenses (1) Archives Archives Select Month October 2021 September 2021 August 2021 July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (13) Srividhya Ragavan (10) Shirin Syed (2) Michael Palmedo (3) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS Excerpts from the Webinar: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Expand the Study of Intellectual Property Rights The Overlooked Role of Copyright in Securing Vaccine Distribution Equity WEBINAR: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
